{"id":"etanercept-autoinjector-a","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions (erythema, itching, pain)"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"7","effect":"Dizziness"},{"rate":"1-3","effect":"Serious infections (including tuberculosis)"},{"rate":"11","effect":"Autoimmune phenomena (anti-dsDNA antibodies)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept works by acting as a soluble TNF receptor that captures circulating TNF-alpha and TNF-beta, preventing them from binding to cell-surface TNF receptors and triggering inflammatory cascades. This reduces systemic inflammation and immune activation in TNF-driven diseases. The autoinjector formulation provides a convenient subcutaneous delivery mechanism for patient self-administration.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:41.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Polyarticular course juvenile rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05891600","phase":"","title":"A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-06-06","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT01729754","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-02-05","conditions":"Plaque Psoriasis","enrollment":1090},{"nctId":"NCT02986139","phase":"PHASE3","title":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-11-29","conditions":"Arthritis, Rheumatoid; Arthritis, Psoriatic","enrollment":111},{"nctId":"NCT01875991","phase":"PHASE4","title":"Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-05","conditions":"Rheumatoid Arthritis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01901185","phase":"PHASE3","title":"Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-11","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":77},{"nctId":"NCT03332719","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Gema Biotech S.A.","startDate":"2016-02","conditions":"Rheumatoid Arthritis","enrollment":168},{"nctId":"NCT03193203","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2017-03-24","conditions":"Healthy","enrollment":50},{"nctId":"NCT00459706","phase":"PHASE3","title":"Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Rheumatoid Arthritis","enrollment":640},{"nctId":"NCT00482170","phase":"PHASE3","title":"Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Psoriasis","enrollment":421}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enbrel®"],"phase":"phase_3","status":"active","brandName":"Etanercept / Autoinjector A","genericName":"Etanercept / Autoinjector A","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}